RUSSELL SKIBSTED
CIK 1308105 · Chief Financial Officer · last filed 2026-07-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$50.9K
Companies
4
Total Filings
25
Lifetime Open-Market Net
$47.0K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PCSA | Chief Financial Officer | 16,689 | $3.05 | $50.9K | $41.7K | 11 | 2026-07-01 |
| ALIMERA SCIENCES INC (ALIM) Delisted | Chief Financial Officer & SVP | 75,500 | $5.54 | $418.3K | $0 | 3 | 2023-11-28 |
| RMTI | See Remarks | — | $6.99 | — | $0 | 2 | 2022-09-13 |
| Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Chief Financial Officer | 2,000 | — | — | $5.3K | 4 | 2018-03-19 |
Recent Filings · Page 2 of 3
25 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-07-18 | PCSA | Grant (A) | — | $0 | EDGAR |
| 2023-11-28 | ALIMERA SCIENCES INC (ALIM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-03-28 | ALIMERA SCIENCES INC (ALIM) Delisted | Grant (A) | +58,000 | $0 | EDGAR |
| 2023-01-10 | ALIMERA SCIENCES INC (ALIM) Delisted | Grant (A) | +17,500 | $0 | EDGAR |
| 2022-09-13 | RMTI | Grant (A) | — | $0 | EDGAR |
| 2020-09-16 | RMTI | Grant (A) | — | $0 | EDGAR |
| 2018-12-20 | — | Mixed | +14,719 | -$8.0K | |
| 2018-10-09 | — | Mixed | +7,359 | -$8.6K | |
| 2018-03-19 | Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-08-25 | Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Buy (P) | +2,000 | $5.3K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.